Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion

Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion

10

May

2023

|

09:59 AM

Europe/Amsterdam

Not intended for U.S. and UK Media

Summary

Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) / QUASAR is expected to enroll around 800 patients in 27 countries / Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual acuity with extended treatment intervals in additional patient populations

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Bayer.com – https://www.bayer.com/media/en-us/bayer-initiates-phase-iii-study-to-investigate-aflibercept-8-mg-in-retinal-vein-occlusion/

Exit mobile version